A Single-arm, Multi-center, Exploratory Safety and Efficacy Study of FCR001 Cell-based Therapy to Induce Donor-specific Tolerance in Previously Transplanted Recipients of a Kidney From a Living Donor, and Safety in FCR001 Donors
Latest Information Update: 06 Mar 2023
At a glance
- Drugs FCR 001 (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Acronyms FREEDOM-2
- Sponsors Talaris Therapeutics
- 28 Feb 2023 Planned End Date changed from 1 Feb 2029 to 28 Feb 2023.
- 28 Feb 2023 Planned primary completion date changed from 1 Dec 2028 to 28 Feb 2023.
- 28 Feb 2023 Status changed from discontinued to withdrawn prior to enrolment.